International researchers have found that major Covid-19 vaccines pose an increased risk of “serious adverse events” that surpasses the “risk reduction for Covid-19 hospitalization.”
The scientific researchers are from Stanford University, UCLA, Louisiana State University, the University of Maryland School of Pharmacy, Navarre Health Service in Spain, and Bond University in Australia. The pre-print academic paper was published in June.
“We sought to investigate the association between FDA-authorized mRNA COVID-19 vaccines and serious adverse events identified by the Brighton Collaboration, using data from the phase III randomized, placebo-controlled clinical trials on which authorization was based,” the researchers state. “We then use the results to illustrate the need for formal harm-benefit analyses of the vaccines that are stratified according to risk of serious COVID-19 outcomes, as well as contextualize the findings against post-authorization observational data.”
The scientific findings suggest that the risk-benefit analysis is trending against mass inoculation for Covid-19 due to the ‘increased risk of serious adverse events’ in examined populations.
“Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively,” the researchers found. “Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9).”
“The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively),” the authors add.
The entire study can be read below:
The Risk Ratio was unfavorable (over 1.0) for each of the vaccines tested, as well as for the Combination approach.
The authors also listed the Serious Adverse Events. The Risk Ratios for acute respiratory distress syndrome and myocarditis/pericarditis are particularly concerning. (It should be added that the events recorded for the sample size are similar in scale for those used to justify Emergency Use Authorizations for both the Pfizer and Moderna vaccines).
There were also concerning incidents of “coagulation disorder” or blood clotting, which can lead to thrombosis and potentially life-threatening outcomes.
The National Institute of Health recently showed that vaccines provide limited protection (~15%) against Long Covid. Furthermore, the Food and Drug Administration dismissed concerns about extremely low Covid mortality risk in young children as well as known side effects and recommended that children six months old to five years old get vaccinated and teenagers get boosted.
This academic study provides real data to show that concerns about Covid vaccine risk outweighing benefits to certain patients are valid. When factoring in that more than 75% of young children already have long-lasting Natural Immunity from prior infection, it has become highly questionable whether the risk-benefit ratio makes sense.